8-K: Tyra Biosciences Executes Share Exchange for Pre-Funded Warrants with Key Investors

Tyra Biosciences has entered into an agreement to exchange 3 million common shares for pre-funded warrants with Boxer Capital and RA Capital.

Summary

• Tyra Biosciences has agreed to exchange 3 million shares of its common stock for pre-funded warrants with Boxer Capital and RA Capital.
• Boxer Capital will exchange 2 million shares for warrants, and RA Capital will exchange 1 million shares for warrants.
• Each warrant allows the holder to purchase one share of common stock at an exercise price of $0.001 per share.
• The warrants are immediately exercisable and do not expire.
• The exercise of the warrants is subject to beneficial ownership limitations of either 9.99% or 19.99%, as selected by the holder.
• Holders can increase or decrease their ownership percentage, but increases are not effective until 61 days after notice to the company.
• The exchange is expected to close on or before October 22, 2024.
• The warrants were issued without registration in reliance on an exemption from the Securities Act of 1933.

Sentiment

Score: 7

Explanation: The document indicates a positive financial maneuver for the company, securing funding through pre-funded warrants. The involvement of established investors is a positive sign, but the potential for future dilution is a moderate concern.

Positives

• The exchange provides Tyra Biosciences with immediate capital without diluting the share price.
• The pre-funded warrants allow the company to receive funds now, with the potential for future equity conversion.
• The involvement of Boxer Capital and RA Capital indicates confidence from established investors.

Negatives

• The exchange could potentially increase the number of outstanding shares if the warrants are exercised.
• The beneficial ownership limitations could restrict the ability of the holders to fully exercise their warrants immediately.

Risks

• The exercise of the warrants could lead to future dilution of existing shareholders.
• The company's share price could be affected by the potential increase in outstanding shares.
• The beneficial ownership limitations could create uncertainty about the timing and extent of warrant exercises.

Future Outlook

The company anticipates the closing of the exchange on or before October 22, 2024. The pre-funded warrants provide potential future capital upon exercise.

Industry Context

This type of transaction is common in the biotech industry, where companies often use pre-funded warrants to raise capital without immediate dilution. It allows investors to participate in the company's potential upside while providing the company with immediate funding.

Comparison to Industry Standards

• Pre-funded warrants are a common financing tool in the biotech sector, similar to those used by companies like Xencor and Arcus Biosciences.
• The exercise price of $0.001 per share is typical for pre-funded warrants, which are often deeply in the money.
• The beneficial ownership limitations are standard to prevent hostile takeovers and maintain control of the company, similar to those seen in other biotech financing agreements.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company benefits from the immediate capital infusion.
• Investors Boxer Capital and RA Capital gain potential future equity in the company.

Next Steps

• The company will complete the exchange of shares for pre-funded warrants on or before October 22, 2024.
• The company will monitor the exercise of the warrants and the potential impact on the share structure.

Key Dates

Keywords

pre-funded warrants, share exchange, equity securities, Boxer Capital, RA Capital, beneficial ownership, exercise price, common stock